Jump to section
Feebris's mission is to transform healthcare globally and make it equitable, personalised and patient-driven. They aim to prevent hospitalisations and suffering from conditions that could have been prevented or treated at home.
Feebris develops ethical AI that improves access to early diagnosis for the most vulnerable patients. The company first developed its AI-powered platform to help community workers in India detect childhood pneumonia. The platform has since evolved to help carers and health assistants identify health risks and deterioration within elderly communities.
Childhood pneumonia is the number one killer of children under the age of 5, thus timely and accurate diagnosis is essential. The Feebris platform connects to tools like a digital stethoscope to identify pathological sounds in the lungs - combining these with other essential symptoms, the platform can identify pneumonia and its severity.
Feebris is also focusing on elderly communities for whom a delayed identification of a health complication often results in avoidable hospitalisations. Elderly people suffer from chronic conditions and are highly susceptible to acute conditions, such as respiratory infections - the Feebris platform can power regular health monitoring among them, for both chronic and acute conditions. Essential clinical information collected in the community can reduce the need for GP appointments and enable independent living.
Feebris aims to develop algorithms for the identification of cardiac conditions (e.g. rheumatic heart disease) and childhood development conditions (e.g. autism).
Steph
Company Specialist at Welcome to the Jungle
Jan 2020
$0.4m
GRANT
May 2019
$1.4m
SEED
This company has top investors
Adam Bacon
(COO)Previously Trading Analyst - Global Markets at HSBC for 4 months and Associate Consultant at Mars & Co for 1 year.
Elina Naydenova
(CEO)Previously Scientific Researcher - Biophysics at University of Warwick for 4 months and Fixed Income Analyst at Credit Suisse also for 4 months.